Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Corcept Therapeutics Inc Market Cap
From what 5 stock analysts predict, the share price for Corcept Therapeutics Inc (CORT) might increase by 27.36% in the next year. This is based on a 12-month average estimation for CORT. Price targets go from $67 to $80. The majority of stock analysts believe CORT is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Corcept Therapeutics Inc has a total of 5 Wall St Analyst ratings. There are 5 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Corcept Therapeutics Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CORT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $80 | Reiterates | Oct 31, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $80 | Maintains | Oct 18, 2024 |
| Joon Lee Truist Securities | Buy | $76 | Maintains | Sep 30, 2024 |
| David Amsellem Piper Sandler | Overweight | $67 | Maintains | Sep 18, 2024 |
| Edward Nash Canaccord Genuity | Buy | $78 | Maintains | Jul 31, 2024 |
| David Amsellem Piper Sandler | Overweight | $38 | Maintains | Jul 30, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $45 | Maintains | Jul 30, 2024 |
| Edward Nash Canaccord Genuity | Buy | $38 | Maintains | Jul 30, 2024 |
| David Amsellem Piper Sandler | Overweight | $35 | Reiterates | Jul 1, 2024 |
| Joon Lee Truist Securities | Buy | $65 | Maintains | Jun 17, 2024 |
| Joon Lee Truist Securities | Buy | $65 | Reiterates | Jun 4, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $40 | Reiterates | May 29, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $40 | Maintains | May 2, 2024 |
| Joon Lee Truist Securities | Buy | $44 | Maintains | May 2, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $38 | Reiterates | Apr 23, 2024 |
| Joon Lee Truist Securities | Buy | $42 | Maintains | Feb 16, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $28 | Maintains | Jan 2, 2024 |
| Edward Nash Canaccord Genuity | Buy | $38 | Maintains | Dec 13, 2023 |
| Joon Lee Truist Securities | Buy | $38 | Upgrade | Nov 6, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $34 | Maintains | Nov 2, 2023 |
When did it IPO
2004
Staff Count
352
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Joseph K. Belanoff M.D.
Market Cap
$6.37B
In 2023, CORT generated $482.4M in revenue, which was a increase of 20.04% from the previous year. This can be seen as a signal that CORT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Corcept (CORT) is noted for its strong growth potential, which may lead to exceptional returns for investors.
Why It Matters - Corcept's solid growth attributes indicate potential for significant financial performance, which can lead to increased stock value and attractive returns for shareholders.
Fri, 06 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Corcept (CORT) has passed the "Recent Price Strength" screening, indicating potential as a profitable investment opportunity for those seeking actively rising stocks.
Why It Matters - Corcept's recent price strength indicates momentum, suggesting potential short-term gains. This could attract momentum-focused investors seeking profitable trades.
Fri, 06 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Corcept (CORT) has a consensus price target suggesting a 26.1% upside. Upward earnings estimate revisions may indicate potential near-term stock gains.
Why It Matters - A 26.1% upside potential implies significant growth opportunity for Corcept (CORT), and rising earnings estimates suggest positive momentum, influencing investor sentiment and decision-making.
Fri, 29 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Corcept (CORT) reported earnings a month ago; investors should monitor upcoming developments and market reactions for future stock performance.
Why It Matters - Corcept's recent earnings report may influence stock performance, affecting investor sentiment and future price movements as analysts assess growth prospects.
Mon, 25 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks Style Scores can help investors identify strong, market-beating stocks for their portfolios.
Why It Matters - Zacks Style Scores provide a systematic approach to identify stocks with high potential, aiding investors in maximizing returns and outperforming the market.
Wed, 27 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Corcept Therapeutics focuses on cortisol-modulating drugs, notably Korlym for Cushing Syndrome. Its strong financials and promising pipeline, including Relacorilant, enhance its investment appeal.
Why It Matters - Corcept Therapeutics' strong financials and unique market position, combined with a promising drug pipeline, suggest significant growth potential despite legal risks, enhancing its attractiveness to investors.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
